Showing 1 - 10 of 92
Background: It has been estimated that major orthopaedic surgery has the highest risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) when compared with other surgery. Two new orally active anticoagulants have recently become licensed in Ireland for the primary prevention...
Persistent link: https://www.econbiz.de/10008459673
Persistent link: https://www.econbiz.de/10012489771
This increase in probability of cost effectiveness, coupled with a substantially reduced potential opportunity loss could influence a decision maker’s confidence in making a reimbursement decision. On discussions with the decision maker we now intend to incorporate the use of VOI into our HTA...
Persistent link: https://www.econbiz.de/10011001469
Background:Background: The National Centre for Pharmacoeconomics, in collaboration with the Health Services Executive, considers the cost effectiveness of all new medicines introduced into Ireland. Health Technology Assessments (HTAs) are conducted in accordance with the existing agreed Irish...
Persistent link: https://www.econbiz.de/10010569818
Objective: To describe the pharmacoeconomic assessment process in Ireland and to provide examples of recent appraisals and the subsequent impact on pricing and reimbursement decisions. Method: The pharmacoeconomic appraisals conducted by the National Centre for Pharmacoeconomics (NCPE) between...
Persistent link: https://www.econbiz.de/10008602824
Persistent link: https://www.econbiz.de/10009404230
Persistent link: https://www.econbiz.de/10009404246
Persistent link: https://www.econbiz.de/10009404280
MS is associated with high levels of healthcare resource consumption and costs, and these costs increase with increasing disability. There is potential to significantly reduce the economic burden of MS through interventions that prevent progression from mild or moderate MS to severe MS, help...
Persistent link: https://www.econbiz.de/10011152173
<Emphasis Type="Bold">Background: The growth of economic analyses and in particular cost-utility analyses (CUA), which use the QALY as a measure of outcome, has heightened the interest in the methodologies used to calculate the QALY. The EQ-5D has produced quite different utility values from that of the SF-6D. This...</emphasis>
Persistent link: https://www.econbiz.de/10011001638